Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics to Participate in Upcoming May Conferences
Oppenheimer Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Cuts Target Price to $12
RBC Capital Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating, Maintains Target Price $4
Piper Sandler Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $6
Piper Sandler Sticks to Its Buy Rating for Fulcrum Therapeutics (FULC)
Q1 2025 Fulcrum Therapeutics Inc Earnings Call
Earnings Call Summary | Fulcrum Therapeutics(FULC.US) Q1 2025 Earnings Conference
Fulcrum Therapeutics Targets Key Data From PIONEER Trial in Q3 2025
Fulcrum Therapeutics Price Target Lowered to $12 From $14 at Oppenheimer
Fulcrum Therapeutics Reports Q1 EPS (28c) Vs. (43c) Last Year
Fulcrum Therapeutics | 10-Q: Q1 2025 Earnings Report
Express News | Fulcrum Therapeutics Expects Current Cash Runway Be Sufficient To Fund Operating Requirements Into At Least 2027
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
Express News | Fulcrum Therapeutics Q1 Net Income USD -17.655 Million
Express News | Fulcrum Therapeutics Q1 Basic EPS USD -0.28
Improved Revenues Required Before Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock's 39% Jump Looks Justified
Earnings Scheduled For May 1, 2025
Uncovering Potential: Fulcrum Therapeutics's Earnings Preview
Earnings Preview: FULC to Report Financial Results Pre-market on May 01